NCT07326371 2026-01-08
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Ruijin Hospital
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT06093841 2025-02-11
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Active not recruiting
NCT05806580 2024-10-23
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital
Phase 4 Recruiting
NCT06479356 2024-08-21
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Recruiting
NCT05370547 2024-03-06
Chidamide Bridging for CAR-T Therapy
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05259813 2023-11-24
Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Withdrawn
NCT04812691 2023-11-22
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Completed
NCT06142188 2023-11-21
Relmacabtagene Autoleucel in Hematologic Malignancies
Shanghai Ming Ju Biotechnology Co., Ltd.
Not yet recruiting
NCT05814848 2023-06-15
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
Changhai Hospital
Phase 4 Not yet recruiting
NCT03355859 2019-07-12
Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Ruijin Hospital
Phase 1 Unknown